Tickernomics

10y

Historical Returns*:

SPY

27.80%

-26.46%

ANIK

SPY

32.66%

-55.29%

ANIK

SPY

108.59%

-68.48%

ANIK

SPY

302.52%

-58.54%

ANIK

*Assumes dividends reinvested

Market Stats:

Market Capitalization($MM)

Enterprise Value($MM)

Daily Volume(MM)

245.89

211.05

0.05

Valuation Metrics:

Price/Earnings Ratio

Price/Sales Ratio

Price/Book Value

FCF Yield(%)

Dividend Yield(%)

EV/EBITDA

-2.52

1.50

1.37

0.30

0.00

-3.98

Profitability Stats:

Operating Margin %(ttm)

Gross Profit %(ttm)

EBITDA Margin %(ttm)

-72.30

3.72

-33.17

Shareholder Value Creation:

Cost of Capital %(est)

ROIC %(ttm)

ROCE %(ttm)

Beta

7.5952

-26.89

-21.73

0.89

Other Earnings and Cash Flow Stats:

Anika Therapeutics Inc. ( ANIK ) Net Income TTM ($MM) is -97.52

Anika Therapeutics Inc. ( ANIK ) Operating Income TTM ($MM) is -34.51

Anika Therapeutics Inc. ( ANIK ) Owners' Earnings Annual ($MM) is 0.00

Anika Therapeutics Inc. ( ANIK ) Current Price to Owners' Earnings ratio is 0.00

Anika Therapeutics Inc. ( ANIK ) EBITDA TTM ($MM) is -25.10

Anika Therapeutics Inc. ( ANIK ) EBITDA Margin is -33.17%

Capital Allocation:

Anika Therapeutics Inc. ( ANIK ) has paid 0.00 dividends per share and bought back -0.133 million shares in the past 12 months

Anika Therapeutics Inc. ( ANIK ) has increased its debt by 27.534 million USD in the last 12 months

Capital Structure:

Anika Therapeutics Inc. ( ANIK ) Interest-bearing Debt ($MM) as of last quarter is 27

Anika Therapeutics Inc. ( ANIK ) Annual Working Capital Investments ($MM) are -20

Anika Therapeutics Inc. ( ANIK ) Book Value ($MM) as of last quarter is 179

Anika Therapeutics Inc. ( ANIK ) Debt/Capital as of last quarter is 15%

Other Balance Sheet Stats:

Anika Therapeutics Inc. ( ANIK ) has 62 million in cash on hand as of last quarter

Anika Therapeutics Inc. ( ANIK ) has 25 million of liabilities due within 12 months, and long term debt 0 as of last quarter

Anika Therapeutics Inc. ( ANIK ) has 14 common shares outstanding as of last quarter

Anika Therapeutics Inc. ( ANIK ) has 0 million USD of preferred stock value

Academic Scores:

Anika Therapeutics Inc. ( ANIK ) Altman Z-Score is 3.82 as of last quarter

Anika Therapeutics Inc. ( ANIK ) Piotroski Score is 3.00 as of last quarter

Corporate Governance:

Anika Therapeutics Inc. ( ANIK ) largest shareholder is owning shares at 0.00 ($MM) value

David Colleran(an insider) Bought 1500 shares of Anika Therapeutics Inc. ( ANIK ) for the amount of $32055.00 on 2022-05-11

3.38% of Anika Therapeutics Inc. ( ANIK ) is held by insiders, and 92.01% is held by institutions

Anika Therapeutics Inc. ( ANIK ) went public on 1993-04-29

About Anika Therapeutics Inc. ( ANIK ) :

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and bone preserving joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief; and Hyvisc, a molecular weight injectable HA veterinary product. The company's joint preservation and restoration product family comprises 150 bone preserving joint technology products, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and orthopedic regenerative solutions, including Hyalofast and Tactoset. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including adhesion barrier, advanced wound care, ear, nose, and throat products, as well as ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.